Cambrex Corp., a manufacturer of small molecule APIs and finished dosage forms, is investing approximately $3 million to increase the capacity at one of its cGMP manufacturing facilities in Milan, Italy. The investment will include the installation of a new 12,000 liter reactor, as well as reconfiguration of the layout to allow for the replacement of existing centrifuges with new, more efficient equipment.
 
The 14,500-sq.-ft. facility manufactures intermediates and APIs under GMP conditions, and this investment is part of a campaign by Cambrex of continuous improvement across its global network of manufacturing sites. In June 2018, Cambrex expanded the R&D labs in Milan, and in 2017 increased the site’s capabilities to handle and manufacture highly potent APIs.
 
“This investment not only increases the overall capacity and capabilities of the facility, but also its flexibility, allowing us to work more efficiently,” said Aldo Magnini, managing director, Cambrex Milan. “The generics portfolio is an important aspect of Cambrex’s business strategy and we have undertaken a number of improvements and expansions at the site to ensure we have the ability to meet the future demands of the industry.”